OncoCyte Corp (OCX)
2.89
-0.06
(-2.03%)
USD |
NASDAQ |
Jul 02, 11:22
OncoCyte Accounts Receivable (Quarterly): 0.161M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.161M |
December 31, 2023 | 0.484M |
September 30, 2023 | 1.882M |
June 30, 2023 | 1.716M |
March 31, 2023 | 1.901M |
December 31, 2022 | 2.012M |
September 30, 2022 | 1.99M |
June 30, 2022 | 1.802M |
March 31, 2022 | 2.122M |
Date | Value |
---|---|
December 31, 2021 | 1.437M |
September 30, 2021 | 1.032M |
June 30, 2021 | 1.025M |
March 31, 2021 | 0.703M |
December 31, 2020 | 0.203M |
September 30, 2020 | 0.366M |
June 30, 2020 | 0.079M |
March 31, 2020 | 0.013M |
December 31, 2019 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2019
2.122M
Maximum
Mar 2022
1.052M
Average
1.028M
Median
Accounts Receivable (Quarterly) Benchmarks
Fonar Corp | 26.92M |
XWELL Inc | 2.90M |
ProPhase Labs Inc | 35.12M |
Applied DNA Sciences Inc | 0.4089M |
Veracyte Inc | 46.66M |